Renal Cell Carcinoma

Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview.- Molecular Genetics of Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes.- Molecular Targets in Renal Tumors: Pathologic Assessment.- Therapeutic Results and Molecular Basis of Activity.- VHL and HIF in Clear Cell Carcinoma.- Molecular Abnormalities and Potential Clinical Applications.- Vascular Endothelial Growth Factor (VEGF): Biologic Aspects and Clinical Approaches.- VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition.- Sunitinib and Axitinib in Renal Cell Carcinoma.- Sorafenib in Renal Cell Carcinoma.- Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.- Integrin a5ß1 as a Novel Therapeutic Target in Renal Cell Carcinoma.- Carbonic Anydrase IX: Biological and Clinical Approaches.- Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biologic and Clinical Studies.- Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis.- PI3K/Akt/mTOR Pathway: A Growth Proliferation Pathway.- EGFR/HER2: Relevance in Renal Cell Carcinoma.- Proteosome - NFkB Signaling Pathway: Relevance in Renal Cell Carcinoma.- The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma.- Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Carcinoma.- EpH2A: A Novel Target in Renal Cell Carcinoma.- Restoring Host Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview.- Molecular Genetics of Inherited Renal Cell Carcinoma: Identification of Targets in the Hereditary Syndromes.- Molecular Targets in Renal Tumors: Pathologic Assessment.- Therapeutic Results and Molecular Basis of Activity.- VHL and HIF in Clear Cell Carcinoma.- Molecular Abnormalities and Potential Clinical Applications.- Vascular Endothelial Growth Factor (VEGF): Biologic Aspects and Clinical Approaches.- VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition.- Sunitinib and Axitinib in Renal Cell Carcinoma.- Sorafenib in Renal Cell Carcinoma.- Additional Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.- Integrin a5ß1 as a Novel Therapeutic Target in Renal Cell Carcinoma.- Carbonic Anydrase IX: Biological and Clinical Approaches.- Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biologic and Clinical Studies.- Chemokines in Renal Cell Carcinoma: Implications for Tumor Angiogenesis and Metastasis.- PI3K/Akt/mTOR Pathway: A Growth Proliferation Pathway.- EGFR/HER2: Relevance in Renal Cell Carcinoma.- Proteosome - NFkB Signaling Pathway: Relevance in Renal Cell Carcinoma.- The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma.- Smac/DIABLO: A Proapoptotic Molecular Target in Renal Cell Carcinoma.- EpH2A: A Novel Target in Renal Cell Carcinoma.- Restoring Host Immunity: How Corrgulatory Molecules are Changing the Approach to Management of Renal Cell Carcinoma.- The Role of Gangliosides in Renal Cell Carcinoma.- Tumor Necrosis Factor – Misnomer and Therapeutic Target.- Molecularly Targeted Staging Strategies in Renal Cell Carcinoma.- Adjuvant therapy for Renal Cell Carcinoma: Targeted Approaches. Immunity: How Coregulatory Molecules are Changing the Approach to Management of Renal Cell Carcinoma.- The Role of Gangliosides in Renal Cell Carcinoma.- Tumor Necrosis Factor – Misnomer and Therapeutic Target.- Molecularly Targeted Staging Strategies in Renal Cell Carcinoma.- Adjuvant therapy for Renal Cell Carcinoma: Targeted Approaches.